Prediction of adverse outcomes in children with sickle cell disease.
about
Deferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing transfusional iron overload in people with sickle cell diseaseEvolving locally appropriate models of care for indian sickle cell diseaseHematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerationsSickle cell disease in childrenSickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Sickle cell disease in childhood: from newborn screening through transition to adult medical care.Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease.Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli.Silent Cerebral Infarct Transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain.Morphological and functional platelet abnormalities in Berkeley sickle cell mice.Proinflammatory cytokines and the hypermetabolism of children with sickle cell diseaseBiomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG TrialThe co-inheritance of alpha-thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival.Erythropoiesis and myocardial energy requirements contribute to the hypermetabolism of childhood sickle cell anemiaIncreased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises.Management of cerebral vasculopathy in children with sickle cell anaemia.How I use hydroxyurea to treat young patients with sickle cell anemia.A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis.Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease.Hydroxyurea and growth in young children with sickle cell disease.Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria.Follow-up of children with hemoglobinopathies diagnosed by the Brazilian Neonatal Screening Program in the State of Pernambuco.Sickle cell diseases and ileus.Pediatric stroke: the importance of cerebral arteriopathy and vascular malformationsSickle cell disease: the neurological complications.Clinical biomarkers in sickle cell disease.Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life.Acute chest syndrome in severity of sickle cell diseases.Salmonella osteomyelitis of the hand in an infant with sickle cell disease.Autonomic nervous system reactivity: children with and without sickle cell disease.Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).Exciting new treatment approaches for pathyphysiologic mechanisms of sickle cell disease.Stem cell transplantation for sickle cell disease: can we reduce the toxicity?Sickle cell anemia as an inflammatory diseaseAnaesthetic management of the child with sickle cell disease.GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study.
P2860
Q24194549-22B66503-E993-4E15-A6A9-3E9C473E8352Q24236463-C6B45DB7-133A-43DD-BDE2-BFD13CF53782Q24242535-D7EAF7D5-B37C-4C5F-83BF-03800E323DC4Q26744706-E2C208F6-4E3A-4616-9EBB-352146FCE33CQ26800236-3393F19C-46BE-4F06-AAE3-6BE6E3833C6BQ26864582-FB4F89E5-FB0B-48E9-B46E-476158A2D44CQ27303155-36B44E4E-DB88-4A35-A06E-B299E6CF3F4AQ27693325-39754E79-400F-4308-BEDB-A2C0B096FD12Q30481575-8D348982-05A4-4218-8987-F6D6DC7DF835Q30640505-67861B34-D06D-4696-8883-289424414C45Q30833776-5A0806AB-CD2A-4DBB-B9F0-925477891997Q31152018-F3126F18-7ABC-411C-B2D1-F7A991C602D2Q33379114-D2EC4575-E34D-4E7E-B994-9F3F53045EF9Q33662087-C3F5A82C-AB13-4578-8B52-812E40960C04Q33789007-BE4B9812-0878-4555-B6B1-3033C4AC875AQ33825794-ECB988E9-1154-474C-8C2C-805D0AFD852BQ33856205-28020309-CF60-47A6-A2AF-DB4DFF11FC93Q33886125-1A9E6778-9FEF-4DB2-996F-C9113A672008Q33904379-FC3112B5-FE80-4A05-B605-C97A54440F00Q33985120-6B7EACE0-2BA9-403A-9ADC-B695A625ED71Q34038874-C2811B5F-3B00-4323-A9B1-7EE7AD4C20E6Q34052855-6EF8F67C-50D6-4796-A1F1-618DEB8FE232Q34086763-FAF987EE-2932-4687-B874-AD417C9108F4Q34360069-0EFC6BFA-0656-445C-B7F9-5D2A0A7FF04FQ34396393-C672BA63-186A-4331-A671-69E1EB4CE1D7Q34415126-FAC1BD35-92BC-470A-BB3A-A4E928213E5BQ34703702-CC979F30-0402-46D8-B271-3F5350A75175Q34733113-0C8823E1-DBF5-4876-80DB-9DF1B83D1721Q34800466-FFEBE536-A429-44A9-844B-508645ECAE43Q34941213-33FCE99E-8B3E-41EC-A73F-CE9B43AE5C4EQ34947693-434328F9-CB0A-4BBA-9328-A3DFFD4E76E4Q35017415-54B27F38-6190-43A3-9FA8-95DE5F2AB9E5Q35069324-BBAA4527-9AA5-42A6-A783-EE962A2227F9Q35087447-ACB34CFF-1242-46D4-8DFB-E839B26A48E4Q35097294-2ADD5299-929D-49C7-BB10-2EA2207EF4B2Q35098084-8DC27ED2-4355-46F6-ABA5-D1D501FF84A0Q35098099-DE23E4D5-E82B-4A83-B4DA-1FAE39E56DAAQ35127288-521D0C3E-C709-4982-A61D-BF8CCF45158DQ35170873-75539132-D926-4CF5-AC9D-9D2AA756943DQ35204794-515CE82F-8115-418D-B7B1-DD883FF3B488
P2860
Prediction of adverse outcomes in children with sickle cell disease.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Prediction of adverse outcomes in children with sickle cell disease.
@en
Prediction of adverse outcomes in children with sickle cell disease.
@nl
type
label
Prediction of adverse outcomes in children with sickle cell disease.
@en
Prediction of adverse outcomes in children with sickle cell disease.
@nl
prefLabel
Prediction of adverse outcomes in children with sickle cell disease.
@en
Prediction of adverse outcomes in children with sickle cell disease.
@nl
P2093
P1476
Prediction of adverse outcomes in children with sickle cell disease.
@en
P2093
Pegelow CH
Sleeper LA
Wethers DL
P356
10.1056/NEJM200001133420203
P407
P577
2000-01-01T00:00:00Z